Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.9463 -0.0637 (-6.31%)
Streaming Delayed Price Updated: 9:56 AM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Recent Federal Procurement Reinforces the Importance of Sustained Investment in Domestic Vaccine Manufacturing and Diversified Medical Countermeasures 
Via TheNewswire.com
Topics Economy
News headline image
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin® as a Potential Complement to Checkpoint Inhibitor Therapy 
Via TheNewswire.com
News headline image
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Publication Highlights Potential for Intratumoral Gedeptin® Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity 
Via TheNewswire.com
News headline image
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape 
Via TheNewswire.com
News headline image
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Largest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S. Host Cities Amid Growing Concerns Regarding Mpox,... 
Via TheNewswire.com
News headline image
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
"Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026 
Via TheNewswire.com
News headline image
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!
Via AB Newswire
Topics Artificial Intelligence
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
Via AB Newswire
News headline image
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum 
Via TheNewswire.com
News headline image
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses 
Via TheNewswire.com
News headline image
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities 
Via TheNewswire.com
News headline image
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA - May 18, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered into a... 
Via TheNewswire.com
News headline image
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
ATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,... 
Via TheNewswire.com
Topics Supply Chain
News headline image
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential 
Via TheNewswire.com
News headline image
GeoVax Announces a Warrant Inducement Transaction
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant... 
Via TheNewswire.com
News headline image
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization 
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.